Mind Medicine (MindMed) (MNMD) Competitors $6.43 -0.15 (-2.28%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$6.50 +0.07 (+1.01%) As of 03/27/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsBuy This Stock MNMD vs. ARQT, TARS, HRMY, TVTX, JANX, IRON, AGIO, APGE, MESO, and VERAShould you be buying Mind Medicine (MindMed) stock or one of its competitors? The main competitors of Mind Medicine (MindMed) include Arcutis Biotherapeutics (ARQT), Tarsus Pharmaceuticals (TARS), Harmony Biosciences (HRMY), Travere Therapeutics (TVTX), Janux Therapeutics (JANX), Disc Medicine (IRON), Agios Pharmaceuticals (AGIO), Apogee Therapeutics (APGE), Mesoblast (MESO), and Vera Therapeutics (VERA). These companies are all part of the "pharmaceutical products" industry. Mind Medicine (MindMed) vs. Arcutis Biotherapeutics Tarsus Pharmaceuticals Harmony Biosciences Travere Therapeutics Janux Therapeutics Disc Medicine Agios Pharmaceuticals Apogee Therapeutics Mesoblast Vera Therapeutics Mind Medicine (MindMed) (NASDAQ:MNMD) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability, community ranking and analyst recommendations. Which has more volatility and risk, MNMD or ARQT? Mind Medicine (MindMed) has a beta of 2.57, indicating that its share price is 157% more volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Which has better valuation and earnings, MNMD or ARQT? Mind Medicine (MindMed) has higher earnings, but lower revenue than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Mind Medicine (MindMed), indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMind Medicine (MindMed)N/AN/A-$95.73M-$2.08-3.09Arcutis Biotherapeutics$196.54M9.71-$262.14M-$1.16-13.87 Do analysts prefer MNMD or ARQT? Mind Medicine (MindMed) currently has a consensus target price of $25.11, indicating a potential upside of 290.53%. Arcutis Biotherapeutics has a consensus target price of $18.80, indicating a potential upside of 16.84%. Given Mind Medicine (MindMed)'s stronger consensus rating and higher probable upside, analysts clearly believe Mind Medicine (MindMed) is more favorable than Arcutis Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mind Medicine (MindMed) 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 3 Strong Buy rating(s) 3.23Arcutis Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Does the media favor MNMD or ARQT? In the previous week, Arcutis Biotherapeutics had 2 more articles in the media than Mind Medicine (MindMed). MarketBeat recorded 12 mentions for Arcutis Biotherapeutics and 10 mentions for Mind Medicine (MindMed). Arcutis Biotherapeutics' average media sentiment score of 1.02 beat Mind Medicine (MindMed)'s score of 0.96 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mind Medicine (MindMed) 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcutis Biotherapeutics 6 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in MNMD or ARQT? Arcutis Biotherapeutics received 13 more outperform votes than Mind Medicine (MindMed) when rated by MarketBeat users. However, 93.22% of users gave Mind Medicine (MindMed) an outperform vote while only 66.67% of users gave Arcutis Biotherapeutics an outperform vote. CompanyUnderperformOutperformMind Medicine (MindMed)Outperform Votes5593.22% Underperform Votes46.78%Arcutis BiotherapeuticsOutperform Votes6866.67% Underperform Votes3433.33% Do insiders & institutionals believe in MNMD or ARQT? 27.9% of Mind Medicine (MindMed) shares are held by institutional investors. 2.3% of Mind Medicine (MindMed) shares are held by insiders. Comparatively, 9.5% of Arcutis Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is MNMD or ARQT more profitable? Mind Medicine (MindMed) has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -140.97%. Mind Medicine (MindMed)'s return on equity of -47.56% beat Arcutis Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mind Medicine (MindMed)N/A -47.56% -35.55% Arcutis Biotherapeutics -140.97%-119.11%-45.95% SummaryMind Medicine (MindMed) beats Arcutis Biotherapeutics on 12 of the 18 factors compared between the two stocks. Remove Ads Get Mind Medicine (MindMed) News Delivered to You Automatically Sign up to receive the latest news and ratings for MNMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNMD vs. The Competition Export to ExcelMetricMind Medicine (MindMed)Medicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$484.62M$1.12B$5.64B$8.06BDividend YieldN/AN/A4.56%4.02%P/E Ratio-2.859.6823.1319.03Price / SalesN/A6.23383.8993.17Price / CashN/A10.4038.1634.64Price / Book3.381.236.944.33Net Income-$95.73M-$53.09M$3.20B$247.06M7 Day Performance-3.31%-2.92%-2.30%-0.52%1 Month Performance-4.03%-15.08%3.10%-3.73%1 Year Performance-32.32%-41.66%11.22%1.74% Mind Medicine (MindMed) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNMDMind Medicine (MindMed)2.4267 of 5 stars$6.43-2.3%$25.11+290.5%-32.3%$484.62MN/A-2.8540Insider TradeAnalyst RevisionNews CoveragePositive NewsARQTArcutis Biotherapeutics2.5663 of 5 stars$17.27+1.5%$18.80+8.9%+67.8%$2.05B$196.54M-9.63150Short Interest ↓Positive NewsTARSTarsus Pharmaceuticals3.1372 of 5 stars$51.38+2.8%$63.67+23.9%+46.5%$1.98B$182.95M-13.5550Insider TradePositive NewsHRMYHarmony Biosciences4.4831 of 5 stars$34.28-2.8%$53.33+55.6%-0.5%$1.97B$714.73M16.25200TVTXTravere Therapeutics2.8006 of 5 stars$21.00+2.3%$30.62+45.8%+165.6%$1.86B$233.18M-5.12460News CoveragePositive NewsJANXJanux Therapeutics2.6466 of 5 stars$31.60+5.5%$92.44+192.6%-21.5%$1.86B$10.59M-26.9330Positive NewsIRONDisc Medicine2.975 of 5 stars$53.46+2.3%$93.80+75.5%-13.3%$1.85BN/A-13.4430Insider TradeAGIOAgios Pharmaceuticals4.3645 of 5 stars$32.18+2.8%$56.57+75.8%+5.9%$1.84B$36.50M2.84390Short Interest ↓Positive NewsAPGEApogee Therapeutics2.4334 of 5 stars$40.89+2.6%$92.17+125.4%-42.4%$1.84BN/A-16.9091Positive NewsMESOMesoblast2.0264 of 5 stars$14.36+3.0%$18.00+25.3%+281.1%$1.83B$5.67M0.0080Gap UpVERAVera Therapeutics3.1437 of 5 stars$27.37+1.1%$64.67+136.3%-39.5%$1.74BN/A-10.4740Positive News Remove Ads Related Companies and Tools Related Companies ARQT Alternatives TARS Alternatives HRMY Alternatives TVTX Alternatives JANX Alternatives IRON Alternatives AGIO Alternatives APGE Alternatives MESO Alternatives VERA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MNMD) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mind Medicine (MindMed) Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mind Medicine (MindMed) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
